IDegLira HIGH Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 145 participants.

Also called NCT03737240

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 145 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03737240
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03737240. Randomized; no masking; primary purpose treatment. Start 2019-01-15 (actual); primary completion 2022-07-08 (actual). Results posted on 2023-09-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
IDegLira HIGH Trial
Condition
Diabetes Mellitus
Intervention (Drug)
IDegLira
Intervention (Drug)
Insulin Degludec (U-100)
Intervention (Drug)
Insulin Aspart
Lead sponsor
Emory University (class: other)
Collaborator
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct03737240
Content hash
9253fdff1b4fc7bfd152bac10928b3fc979107d18445d9041f6b005be2f8a2a4